natgillin/translations-raw huggingface dataset:
The 2x2 factorial design COMMIT trial included 45,852 patients presenting within 24 hours of the onset of the symptoms of suspected MI with supporting ECG abnormalities (i.e. ST elevation, ST depression or left bundle-branch block).
COMMIT ispitivanje faktorskog dizajna 2x2, uključivalo je 45 852 bolesnika koji su unutar posljednja 24 sata pretrpjeli simptome suspektne na infarkt miokarda, s pratećim abnormalnostima EKG-a (primjerice ST elevacija, ST depresija ili blok lijeve grane snopa).
A pharmacodynamic interaction between clopidogrel and heparin is possible, leading to increased risk of bleeding.
Farmakodinamička interakcija između klopidogrela i heparina je moguća i može povećati rizik od krvarenja.
The incidence of clinically significant bleeding was similar to that observed when thrombolytic agents and heparin are co-administered with ASA (see section 4.8).
Incidencija klinički značajnog krvarenja bila je slična onoj zamijećenoj pri istodobnoj primjeni trombolitika i heparina s ASK (vidjeti dio 4.8.).
Clopidogrel Teva Generics B.V. is taken to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death).
Klopidogrel Teva Generics B.V. uzimaju odrasli za sprječavanje stvaranja krvnih ugrušaka (tromba) u otvrdnutim krvnim žilama (arterijama), a taj poremećaj zove se aterotromboza i može dovesti do aterotrombotičkih događaja (kao što su moždani udar, srčani udar ili smrt).
In a small number of cases, bleeding in the eye, inside the head, the lung or the joints has also been reported.
U manjem su broju slučajeva zabilježena i krvarenja u oku, glavi, plućima ili zglobovima.
Esomeprazole is expected to give a similar interaction with clopidogrel.
Očekuju se i slične interakcije između esomeprazola i klopidogrela.
Medicinal products that inhibit CYP2C19 include omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, ciprofloxacin, cimetidine, carbamazepine, oxcarbazepine and chloramphenicol.
Lijekovi koji inhibiraju CYP2C19 uključuju omeprazol i esomeprazol, fluvoksamin, fluoksetin, moklobemid, vorikonazol, flukonazol, tiklopidin, ciprofloksacin, cimetidin, karbamazepin, okskarbazepin i kloramfenikol.
Film coating:
Film-ovojnica:
This benefit was mostly driven by the statistically significant reduction in the incidence of MI [287 (4.6%) in the clopidogrel treated group and 363 (5.8%) in the placebo treated group].
Na taj učinak najviše je utjecalo statistički značajno smanjenje incidencije infarkta miokarda [287 (4,6%) u skupini koja je primala klopidogrel i 363 (5,8%) u skupini koja je primala placebo].
• Your doctor may order blood tests
Liječnik će možda odrediti da Vam se naprave pretrage krvi.
Mean peak plasma levels of unchanged clopidogrel (approximately 2.2-2.5 ng/ml after a single 75 mg oral dose) occurred approximately 45 minutes after dosing.
Srednje vršne razine nepromijenjenog klopidogrela u plazmi (oko 2,2 - 2,5 ng/ml nakon jednokratne oralne doze od 75 mg) postižu se otprilike 45 minuta nakon uzimanja lijeka.
Thrombolytics: the safety of the concomitant administration of clopidogrel, fibrin or non-fibrin specific thrombolytic agents and heparins was assessed in patients with acute myocardial infarction.
Trombolitici: sigurnost istodobne primjene klopidogrela, fibrinskih ili afibrinskih specifičnih trombolitika i heparina procjenjivana je u bolesnika s akutnim infarktom miokarda.
The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and CYP2C19*3 alleles correspond to reduced metabolism.
CYP2C19*1 alel odgovara potpuno funkcionalnom metabolizmu, dok su CYP2C19*2 i CYP2C19*3 aleli nefunkcionalni.
Pharmacogenetics
Farmakogenetika
Overall, clopidogrel 75 mg/day was comparable to ASA 325 mg/day in CAPRIE regardless of age, gender and race.
Sveukupno su, u studiji CAPRIE, podaci za klopidogrel u dozi od 75 mg/dan bili slični podacima za ASK u dozi od 325 mg/dan, bez obzira na dob, spol ili rasu.
The clinically relevant adverse reactions observed in the CAPRIE, CURE, CLARITY and COMMIT studies are discussed below.
Klinički značajne nuspojave opažene u studijama CAPRIE, CURE, CLARITY i COMMIT i ACTIVE-A opisane su u daljnjem tekstu.
The pharmacokinetics of digoxin or theophylline were not modified by the co-administration of clopidogrel.
Farmakokinetika digoksina ili teofilina nije se mijenjala pri istodobnoj primjeni klopidogrela.
Acetylsalicylic acid (ASA): ASA did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation, but clopidogrel potentiated the effect of ASA on collagen-induced platelet aggregation.
Acetilsalicilna kiselina (ASK): ASK nije promijenila klopidogrelom posredovanu inhibiciju agregacije trombocita koju inducira ADP, ali je klopidogrel potencirao učinak ASK na agregaciju trombocita posredovanu kolagenom.
Clopidogrel significantly reduced the incidence of new ischaemic events (combined end point of myocardial infarction, ischaemic stroke and vascular death) when compared to ASA.
U usporedbi s ASK, klopidogrel je značajno smanjio incidenciju novih ishemijskih događaja (kombinirani ishod infarkta miokarda, ishemijskog moždanog udara i vaskularne smrti).
Luxembourg/Luxemburg Teva Pharma Belgium S.A. Tél/Tel: +32 3 820 73 73
Teva Pharma Belgium N.V./S.A./AG Tél/Tel: +32 3 820 73 73
Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype.
Farmakokinetika i antitrombocitni učinak aktivnog metabolita klopidogrela, mjereni u ex vivo testovima agregacije trombocita, razlikuju se ovisno o genotipu CYP2C19.
After a single oral dose of 75 mg, clopidogrel has a half-life of approximately 6 hours.
Nakon jednokratne oralne primjene klopidogrela u dozi od 75 mg, poluvijek klopidogrela iznosio je otprilike 6 sati.
Pink, round and slightly convex film-coated tablets.
Ružičaste, okrugle i blago ispupčene, filmom obložene tablete.
The benefits observed with clopidogrel were independent of other acute and long-term cardiovascular therapies (such as heparin/LMWH, GPIIb/IIIa antagonists, lipid lowering medicinal products, beta blockers, and ACE-inhibitors).
Zabilježena korist liječenja klopidogrelom bila je neovisna o drugoj akutnoj ili dugotrajnoj kardiovaskularnoj terapiji (kao što su: heparin/heparini male molekularne težine, antagonisti GPIIb/IIIa, lijekovi za snižavanje kolesterola, beta blokatori i ACE inhibitori).
The primary endpoint was the occurrence of the composite of an occluded infarct-related artery on the predischarge angiogram, or death or recurrent MI before coronary angiography.
Primarni ishod bio je pojava okludirane koronarne arterije koja je najvjerovatnije dovela do infarkta miokarda na angiogramu učinjenom prije otpusta, smrt ili ponovljeni infarkt miokarda prije koronarne angiografije.
No clinically significant pharmacodynamic interactions were observed when clopidogrel was co-administered with atenolol, nifedipine, or both atenolol and nifedipine.
Nisu primijećene klinički značajne farmakodinamičke interakcije pri istodobnoj primjeni klopidogrela i atenolola, odnosno nifedipina, ili klopidogrela i ta dva lijeka zajedno.
Heparins were administered in more than 90% of the patients and the relative rate of bleeding between clopidogrel and placebo was not significantly affected by the concomitant heparin therapy.
Heparin je primalo više od 90% bolesnika, a na relativni stupanj krvarenja u skupini koja je primala klopidogrel i onoj koja je primala placebo nije značajno utjecalo istodobno liječenje heparinom.
Adverse reactions that occurred either during clinical studies or that were spontaneously reported are presented in the table below.
Nuspojave prikupljene u kliničkim studijama kao i nuspojave prijavljene spontano, nabrojene su u tablici.
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favor of clopidogrel (95% CI: 24, 47%; p<0.001), mainly related to a reduction in occluded infarct-related arteries.
Petnaest posto (15,0%) bolesnika u skupini s klopidogrelom i 21,7% u skupini s placebom dostigli su primarni ishod, što predstavlja apsolutno smanjenje od 6,7% i smanjenje izgleda (engl. odds reduction) od 36% u korist klopidogrela (95% CI: 24, 47%; p<0,001), većinom povezano sa smanjenjem okluzije arterija povezanih s infarktom.
If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed clopidogrel in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever.
Ako ste imali jaku bol u prsištu (nestabilna angina ili srčani udar), liječnik Vam može propisati Klopidogrel Teva Generics B.V u kombinaciji s acetilsalicilatnom kiselinom, tvari prisutnom u mnogim lijekovima za ublažavanje boli i snižavanje temperature.
In TRITON-TIMI 38 and 3 of the cohort studies (n= 3,516; Collet, Sibbing, Giusti), patients with an impaired metaboliser status (intermediate and poor combined) had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolisers.
U studiji TRITON-TIMI 38 i 3 kohortne studije (Collet, Sibbing, Giusti), stopa kardiovaskularnih događaja (smrt, infarkt miokarda i moždani udar) ili tromboze stenta bila je veća u kombiniranoj skupini bolesnika sa statusom umjerenih ili slabih metabolizatora nego u brzih metabolizatora.
The active thiol metabolite which has been isolated in vitro, binds rapidly and irreversibly to platelet receptors, thus inhibiting platelet aggregation.
Aktivni tiolni metabolit, koji je izoliran in vitro, brzo se i ireverzibilno veže na receptore na trombocitima i time inhibira agregaciju trombocita.
The efficacy of clopidogrel was observed independently of the dose of ASA (75-325 mg once daily).
Djelotvornost klopidogrela nije ovisila o dozi ASK (75 do 325 mg jedanput na dan).
CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite.
CYP2C19 je uključen u formiranje aktivnog metabolita i 2-okso-klopidogrel intermedijarnog metabolita.
• Patients suffering from acute coronary syndrome: - Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA).
odraslih bolesnika koji boluju od akutnog koronarnog sindroma: - Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina ili non-Q infarkt miokarda), uključujući bolesnike koji se podvrgavaju ugradnji stenta nakon perkutane koronarne intervencije, u kombinaciji s acetilsalicilatnom kiselinom (ASK).
28 film-coated tablets 28x1 film-coated tablets 30 film-coated tablets 30x1 film-coated tablets 50 film-coated tablets 50x1 film-coated tablets 56 film-coated tablets 56x1 film-coated tablets 84 film-coated tablets 84x1 film-coated tablets 90 film-coated tablets 90x1 film-coated tablets 100 film-coated tablets 100x1 film-coated tablets
28 filmom obloženih tableta 28x1 filmom obloženih tableta 30 filmom obloženih tableta 30x1 filmom obloženih tableta 50 filmom obloženih tableta 50x1 filmom obloženih tableta 56 filmom obloženih tableta 56x1 filmom obloženih tableta 84 filmom obložene tablete 84x1 filmom obloženih tableta 90 filmom obloženih tableta 90x1 filmom obloženih tableta 100 filmom obloženih tableta 100x1 filmom obloženih tableta
If you have any further questions on the use of this product, ask your doctor or pharmacist.
U slučaju bilo kakvih pitanja u vezi s primjenom ovog lijeka obratite se svom liječniku ili ljekarniku.
Oral anticoagulants: the concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.4).
Oralni antikoagulansi: ne preporučuje se istodobna primjena klopidogrela i oralnih antikoagulansa jer se može povećati intenzitet krvarenja (vidjeti dio 4.4.).
Patients received clopidogrel (75 mg/day, n=22,961) or placebo (n=22,891), in combination with ASA (162 mg/day), for 28 days or until hospital discharge.
Bolesnici su primali klopidogrel (75 mg na dan, n=22 961) ili placebo (n=22 891), u kombinaciji s ASK (162 mg na dan), u trajanju do 28 dana ili do otpusta iz bolnice.
Driving and using machines Clopidogrel Teva Generics B.V. is unlikely to affect your ability to drive or to use machines.
Klopidogrel Teva Generics B.V. ne bi trebao utjecati na Vašu sposobnost upravljanja vozilima ili strojevima.
Like all medicines, Clopidogrel Teva Generics B.V. can cause side effects, although not everybody gets them.
Kao i svi drugi lijekovi, ovaj lijek može uzrokovati nuspojave iako se one neće javiti kod svakoga.
Clopidogrel is a prodrug, one of whose metabolites is an inhibitor of platelet aggregation.
Klopidogrel je predlijek, čiji je jedan metabolit inhibitor agregacije trombocita.
In patients who remained on therapy within five days of bypass graft surgery, the event rate was 9.6% for clopidogrel+ASA, and 6.3% for placebo + ASA.
U bolesnika koji su terapiju nastavili primati i unutar 5 dana do ugrađivanja premosnice, stopa krvarenja bila je 9,6% za klopidogrel uz ASK, odnosno 6,3% za placebo uz ASK.
As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors.
Kao i u slučaju drugih antitrombocitnih lijekova, klopidogrel s oprezom treba davati bolesnicima koji su izloženi povećanom riziku od krvarenja zbog povreda, kirurških zahvata ili drugih patoloških stanja te bolesnicima koji se liječe s ASK, heparinom, inhibitorima glikoproteina IIb/IIIa ili nesteroidnim protuupalnim lijekovima (NSAIL), uključujući Cox-2 inhibitore.
If you forget for more than 12 hours, simply take the next single dose at the usual time.
Ako se ne sjetite propuštene doze u roku od 12 sati, sljedeću uzmite u uobičajeno vrijeme.
This was consistent across subgroups of patients defined by baseline characteristics, and type of fibrinolytic or heparin therapy.
Konzistentni podaci dobiveni su i u podskupinama bolesnika koje su definirane prema početnim karakteristikama i tipu terapije fibrinoliticima ili heparinom.
Then, the usual dose is one 75 mg tablet of Clopidogrel Teva Generics B.V. per day to be taken orally with or without food, and at the same time each day.
Nakon toga, preporučena doza lijeka Klopidogrel Teva Generics B.V. je jedna tableta od 75 mg na dan koja se uzima kroz usta s obrokom ili između obroka, u isto vrijeme svaki dan.
Since clopidogrel is metabolised to its active metabolite partly by CYP2C19, use of medicinal products that inhibit the activity of this enzyme would be expected to result in reduced drug levels of the active metabolite of clopidogrel.
S obzirom da se klopidogrel djelomično metabolizira do svog aktivnog metabolita pomoću enzima CYP2C19, očekuje se da će primjena lijekova koji inhibiraju aktivnost ovog enzima rezultirati smanjenom koncentracijom aktivnog metabolita klopidogrela.
Bleeding is the most common reaction reported both in clinical studies as well as in post-marketing experience where it was mostly reported during the first month of treatment.
Najčešće prijavljena nuspojava u kliničkim ispitivanjima i praćenju nakon stavljanja lijeka u promet je krvarenje, a zabilježeno je najčešće tijekom prvog mjeseca liječenja.
Subsequent metabolism of the 2-oxo-clopidogrel intermediate metabolite results in formation of the active metabolite, a thiol derivative of clopidogrel.
Naknadni metabolizam 2-okso-klopidogrela rezultira nastajanjem aktivnog metabolita, tiolnog derivata klopidogrela.
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min) inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day.
Nakon ponovljenih doza od 75 mg klopidogrela na dan, inhibicija ADP-om inducirane agregacije trombocita bila je niža (25%) u ispitanika s teško narušenom funkcijom bubrega (klirens kreatinina od 5 do 15 ml/min) nego u zdravih ispitanika, iako je produljenje vremena krvarenja bilo slično onom zabilježenom u zdravih bolesnika koji su primali 75 mg klopidogrela na dan.
Co-administration of heparin had no effect on the inhibition of platelet aggregation induced by clopidogrel.
Istodobna primijena heparina nije utjecala na inhibiciju agregacije trombocita induciranu klopidogrelom.
Therapeutic experience with clopidogrel is limited in patients with renal impairment.
Terapijsko je iskustvo s klopidogrelom u bolesnika s narušenom funkcijom bubrega ograničeno.
The CURE study included 12,562 patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), and presenting within 24 hours of onset of the most recent episode of chest pain or symptoms consistent with ischaemia.
Studija CURE uključivala je 12 562 bolesnika s akutnim koronarnim sindromom bez elevacije STsegmenta (nestabilna angina ili non-Q infarkt miokarda), koji su u zadnja 24 sata imali epizodu boli u prsištu ili simptome ishemije.
Each film-coated tablet contains 75 mg of clopidogrel (as hydrochloride).
Jedna filmom obložena tableta sadrži 75 mg klopidogrela (u obliku klopidogrelklorida).
If any of the situations mentioned below apply to you, you should tell your doctor before taking Clopidogrel Teva Generics B.V.:
Ako se na Vas odnosi bilo koje od stanja navedenih u daljnjem tekstu, morate obavijestiti liječnika prije nego što uzmete Klopidogrel Teva Generics B.V.:
• Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
odraslih bolesnika koji su pretrpjeli infarkt miokarda (u rasponu od nekoliko do najviše 35 dana), ishemijski moždani udar (u rasponu od 7 dana do najviše 6 mjeseci) ili imaju utvrđenu bolest perifernih arterija.
Very rare side effects (affects less than 1 patient in 10,000): Jaundice; severe abdominal pain with or without back pain; fever, breathing difficulties sometimes associated with cough; generalised allergic reactions; swelling in the mouth; blisters of the skin; skin allergy; inflammation of the mouth (stomatitis); decrease in blood pressure; confusion; hallucinations; joint pain; muscular pain; changes in the way things taste.
Žutica; jaka bol u trbuhu s bolovima u leđima ili bez njih; vrućica, teškoće pri disanju, ponekad povezane s kašljem; generalizirane alergijske reakcije (primjerice, sveukupni osjećaj vrućine s iznenadnom općom nelagodom do nesvjestice); oticanje u ustima; mjehurići na koži; kožne alergijske reakcije; upala u usnoj šupljini (stomatitis); pad krvnoga tlaka; zbunjenost; halucinacije; bol u zglobovima, bol u mišićima, poremećaj okusa hrane.
In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint (CV death, MI, stroke or refractory ischaemia).
U tzv. post-hoc analizi 2.172 bolesnika (17% ukupne CURE populacije) koji su se podvrgli ugradnji stenta (Stent-CURE), podaci su pokazali da je klopidogrel u usporedbi s placebom, pokazao značajno smanjenje relativnog rizika od 26,2% za koprimarni ishod (kardiovaskularna smrt, infarkt miokarda, moždani udar) kao i značajno smanjenje relativnog rizika od 23,9% za drugi koprimarni ishod (kardiovaskularna smrt, infarkt miokarda, moždani udar ili refraktorna ishemija).
It is unknown whether clopidogrel is excreted in human breast milk.
Nije poznato izlučuje li se klopidogrel u majčino mlijeko.
4.6 Pregnancy and lactation
4.6 Plodnost, trudnoća i dojenje
Antacids did not modify the extent of clopidogrel absorption.
Antacidi nisu utjecali na opseg apsorpcije klopidogrela.
Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:
Prevencija aterotrombotičkih događaja Klopidogrel je indiciran u:
Patients should be told that it might take longer than usual to stop bleeding when they take clopidogrel (alone or in combination with ASA), and that they should report any unusual bleeding (site or duration) to their physician.
Bolesnicima koji uzimaju klopidogrel (kao monoterapiju ili u kombinaciji s ASK) potrebno je objasniti da će krvarenje možda trajati dulje nego obično i da moraju obavijestiti liječnika o svakom neočekivanom krvarenju (odnosno o mjestu i trajanju krvarenja).
The concomitant administration of clopidogrel with oral anticoagulants is not recommended since it may increase the intensity of bleedings (see section 4.5).
Ne preporučuje se istodobna primjena klopidogrela i drugih oralnih antikoagulansa, jer to može pojačati intenzitet krvarenja (vidjeti dio 4.5.).
− Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily).
Akutni koronarni sindrom bez elevacije ST-segmenta (nestabilna angina ili non-Q infarkt miokarda): liječenje klopidogrelom treba započeti s jednokratnom udarnom dozom od 300 mg, a zatim nastaviti sa 75 mg jedanput na dan (uz acetilsalicilnu kiselinu (ASK)
As a precaution concomitant use of medicinal products that inhibit CYP2C19 should be discouraged (see section 4.5 for a list of CYP2C19 inhibitors, see also section 5.2).
Kao mjera opreza, ne preporučuje se istodobna primjena lijekova koji su jaki ili umjereni inhibitori CYP2C19 (za popis inhibitora CYP2C19 vidjeti dio 4.5, također vidjeti dio 5.2).
Appropriate therapy should be considered if bleedings are observed.
Ako se primijeti krvarenje, treba razmotriti primjerenu terapiju.
In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR =4.0%; CI: -22.5 to 11.7 [p=0.639]).
U bolesnika koji su u studiju uključeni samo zbog nedavnog infarkta miokarda, klopidogrel je bio brojčano slabiji, ali se statistički nije razlikovao od ASK (RRR = -4,0%; CI: -22,5 do 11,7 [p=0,639]).
Patients were randomized to clopidogrel 75 mg/day or ASA 325 mg/day, and were followed for 1 to 3 years.
Bolesnici su randomizirani u skupine koje su primale 75 mg klopidogrela ili 325 mg acetilsalicilatne kiseline na dan te su praćeni od 1 do 3 godine.
− ST segment elevation acute myocardial infarction: clopidogrel should be given as a single daily dose of 75 mg initiated with a 300 mg loading dose in combination with ASA and with or without thrombolytics.
Akutni infarkt miokarda s elevacijom ST-segmenta: liječenje klopidogrelom provodi se jednom dnevnom dozom od 75 mg, a započinje udarnom dozom od 300 mg u kombinaciji s ASK te s tromboliticima ili bez njih.